Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors
March 27 (Reuters) - Carna Biosciences Inc <4572.T>:Says it and Sumitomo Dainippon Pharma Co Ltd <<<4506.T>>> , signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent.
Latest Developments forSumitomo Chemical Co Ltd
- Sumitomo Chemical Co Ltd - Appoints New Chairman And New President
- Sumitomo Chemical to acquire 51 pct stake in Wuxi-based electronic materials tech firm
- Sumitomo Chemical Co to buy stake exceeding 80% in Botanical Resources Australia - Nikkei
- Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe